Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solifenacin/Tamsulosin Combination vs Tamsulosin in BPH/LUTS
NCT02972268Phase 3Completed
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
- Start
- Feb 2016
- Primary completion
- Nov 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of solifenacin in benign prostatic hyperplasia (BPH) (2 arms), sponsored by Jeil Pharmaceutical Co., Ltd. Primary endpoints: Total Urgency and Frequency Score at 12 weeks and International Prostate Symptom Score at 12 weeks. Started Feb 2016; status: completed.
02
Drugs
solifenacin
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT02972268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02972268.